AKT1 and Parkinson disease: In PD, a randomised placebo-controlled trial of exenatide in 60 patients followed up for 48 weeks similarly showed target engagement of brain insulin and protein kinase B (Akt)/phosphorylated mechanistic target of rapamycin signalling pathways correlating with disease progression.27